



CURRICULUM VITAE
Timothy F. O’Neill, MD
 Joined Los Alamitos Cardiovascular as a partner in 1997

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | website: www.losalcardio.com

Specialties:	Internal Medicine, Cardiology
Board Certifications:	<ul style="list-style-type: none"> • Certified in Cardiovascular Disease American Board of Internal Medicine 1993 (Recertification 2009) • Certified in Internal Medicine American Board of Internal Medicine 1990 • National Board Parts I,II,III National Board of Medical Examiners 1985 – 1988
Research Experience:	<ul style="list-style-type: none"> • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction. Sub-Investigator 2017 Sponsor: Amgen NCT02929329: https://clinicaltrials.gov/ct2/show/NCT02929329 • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction. Sub-Investigator 2017 Sponsor: Novartis NCT02887183: https://clinicaltrials.gov/ct2/show/NCT02887183

- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
 Sub-Investigator | 2016 – Present
 Sponsor: CVRx, Inc.
 NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>
- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
 Sub-Investigator | 2016
 Sponsor: Gilead/ICON
- **THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
 Sub-Investigator | 2015 – Present
 Sponsor: AstraZeneca
 NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>
- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
 Sub-Investigator | 2015
 Sponsor: Amgen, Evidera
- **DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events:** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
 Sub-Investigator | 2013 – Present
 Sponsor: AstraZeneca
 NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>
- **ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
 Sub-Investigator | 2013 – Present
 Sponsor: Sanofi
 NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>

- **SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**
 Sub-Investigator | 2013 – 2017
 Sponsor: Yale University School of Medicine/NIH
 NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>
- **RivaroxAFL3003:** An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
 Sub-Investigator | 2013
 Sponsor: Janssen Scientific Affairs/Johnson & Johnson
- **Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.**
 Sub-Investigator | 2013
 Sponsor: Tasly Pharmaceuticals
 NCT0169580 | <http://clinicaltrials.gov/ct2/show/NCT0169580>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
 Sub-Investigator | 2013
 Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
 NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>
- **User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.**
 Sub-Investigator | 2012
 Sponsor: Alere San Diego
- **Mission® PT Coagulation Monitoring System Clinical Study.**
 Sub-Investigator | 2012
 Sponsor: ACON Laboratories, INC.
- **The “BRIDGE” Trial (1U01HL08675501A1):** Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
 Sub-Investigator | 2012 – 2015
 Sponsor: National Institutes of Health (NIH) – National Heart, Lung and Blood Institute (NHLBI)

NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>

- **GLORIA-AF 1160.129:** Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
Sub-Investigator | 2012 – Present
Sponsor: Boehringer Ingelheim
NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>
- **BRADY-CARE:** Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
Sub-Investigator | 2010 – 2012
Sponsor: St. Jude Medical Center
NCT01062126 | <http://clinicaltrials.gov/ct2/show/NCT01062126>
- **The PROMISE Trial:** PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
Sub-Investigator | 2010 – 2014
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
NCT01174550 | <http://clinicaltrials.gov/ct2/show/record/NCT01174550>
- **ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Sub-Investigator | 2010 – Present
Sponsor: Janssen Scientific Affairs, LLC
Collaborator: Duke Clinical Research
NCT01165710 | <http://clinicaltrials.gov/ct2/show/NCT01165710>
NCT01701817 | <http://clinicaltrials.gov/ct2/show/NCT01701817>
- **RATE:** Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00837798 | <http://clinicaltrials.gov/ct2/show/NCT00837798>
- **FREEDOM:** A Frequent Optimization Study the Quick Opt™ Method.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00418314 | <http://clinicaltrials.gov/ct2/show/NCT00418314>
- **ENGAGE:** Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
Sub-Investigator | 2009 – 2015
Sponsor: Daiichi Sankyo Pharma Development

	<p>NCT00781391 http://clinicaltrials.gov/ct2/show/record/NCT00781391</p>
<p>Current Hospital Appointments:</p>	<ul style="list-style-type: none"> • Los Alamitos Medical Center 3751 Katella Avenue Los Alamitos, California 90720 • MemorialCare Health System Long Beach Memorial Medical Center 2801 Atlantic Avenue Long Beach, California 90801 • Lakewood Regional Medical Center 3700 South Street Lakewood, California 90712
<p>Work History:</p>	<ul style="list-style-type: none"> • Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc. Cardiologist Los Alamitos, California February 1997 – Present • Heart Institute of the Desert Rancho Mirage, California October 1993 – February 1997
<p>Education:</p>	<ul style="list-style-type: none"> • Pacemaker Fellowship Long Beach Memorial Medical Center Long Beach, California July 1992 – June 1993 • Cardiology Fellowship University of California, Irvine Medical Center Irvine, California July 1990 – June 1993 • Internal Medicine Residency University of California, Irvine Medical Center Irvine, California June 1987 – June 1990 • University of New Mexico School of Medicine Doctor of Medicine Degree Albuquerque, New Mexico August 1983 – May 1987

	<ul style="list-style-type: none"> • Undergraduate Education Creighton University Omaha, Nebraska Bachelor of Arts Degree in History, <i>Summa Cum Laude</i> August 1979 – May 1983
Educational Honors and Awards:	<ul style="list-style-type: none"> • Outstanding Intern Commendation Veteran’s Administration Medical Center Long Beach, California 1987 • Four Superior Scholastic Achievement Awards Creighton University 1980 – 1983 • Graduated Summa Cum Laude Creighton University 1983
Clinical Expertise:	<p>Non-Invasive Cardiology Echocardiography, TEE, Dobutamine and Stress Echo</p> <p>Invasive Cardiology Catheterization, Permanent Pacemaker Implantation</p>
Medical License:	California , 1989